Ascendis Pharma AS (ASND)

Healthcare · Biotechnology
$225.90 -0.07% on the day Market cap $13.6B 52-week range $186.05 to $282.15 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Ascendis Pharma AS's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

D

Five factors scored 1 to 9 from ASND's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation2
Profitability2
Growth9
Financial health3

Key numbers

P/E (trailing)24.9x
P/E (forward)42.2x
Price / free cash flow312.5x
EV / EBITDA-20.7x
Price / sales15.7x
Price / book23.8x
Revenue growth+42.3%
Operating margin-18.9%
Net margin-31.7%
Return on equity—
Dividend yield—
Debt / equity—

Results from SEC filings

Fiscal years, from Ascendis Pharma AS's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$8M$51M$267M$364M$720M
Net income-$384M-$583M-$481M-$378M-$228M
Free cash flow-$441M-$510M-$470M——
EPS (diluted)-$7.00-$10.40-$8.55-$6.53-$3.76
Operating margin-5808.6%-1097.9%-170.8%-76.7%-18.9%

Where the revenue comes from

Revenue by regions, fiscal 2025.

USA$546M76%
Europe$121M17%
Rest of World$53M7%

Superinvestors who own ASND

From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Ron Baron
Baron Capital (BAMCO)
New position $400,0800.00%Q2 2026

Insider buying

Open-market purchases by Ascendis Pharma AS's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of ASND in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when ASND trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Ascendis Pharma AS insiders buying the stock?

No open-market insider purchases of ASND in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Ascendis Pharma AS?

1 of the superinvestors Investingly tracks hold ASND in their latest 13F, including Ron Baron.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.